NeuroSense Therapeutics

(NASDAQ) NRSN

Current Price$0.70

Market Cap$25.56M

Since IPO (2021)-82%

5 YearN/A

1 Year-62%

1 Month-11%

NeuroSense Therapeutics Financials at a Glance

Market Cap

$25.56M

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.66M

EPS (TTM)

$0.00

P/E Ratio

-1.24

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.70

Volume

231,750.187

Open

$0.75

Price

$0.70

Volume

231,750.187

Open

$0.75

Previous Close

$0.71

Daily Range

$0.67 - $0.75

52-Week Range

$0.63 - $2.19

Estimated Earnings Date

Jun 30, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.70

Volume

231,750.187

Open

$0.75

Previous Close

$0.71

Daily Range

$0.67 - $0.75

52-Week Range

$0.63 - $2.19

Estimated Earnings Date

Jun 30, 2026

NRSN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeuroSense Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Alon Ben-Noon, MBA

Website

www.neurosense-tx.com

Headquarters

Herzliya, 4672562, IL

NRSN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

173600.00%

Return on Capital

N/A

Return on Assets

-633.27%

Earnings Yield

-80.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.56M

Shares Outstanding

35.35M

Volume

231.75K

Avg. Volume

163.69K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$8.57M

EBITDA

-$8.55M

Operating Cash Flow

-$2.00K

Capital Expenditure

$0.00

Free Cash Flow

-$2.00K

Cash & ST Invst.

$166.00K

Total Debt

$170.00K

NeuroSense Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$25.56M

N/A

Market Cap/Employee

$1.50M

N/A

Employees

N/A

Net Income

-$2.35M

-174.7%

EBITDA

-$2.34M

-175.0%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$166.00K

-51.7%

Total Debt

$170.00K

+794.7%

Accounts Receivable

$33.00K

-91.9%

Inventory

$0.00

N/A

Long Term Debt

$72.00K

+278.9%

Short Term Debt

$98.00K

N/A

Return on Assets

-6.33%

N/A

Return on Invested Capital

4.34%

N/A

Free Cash Flow

-$2.00K

N/A

Operating Cash Flow

-$2.00K

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KLTOKlotho Neurosciences, Inc.

KLTOKlotho Neurosciences, Inc.$0.38-7.10%

NERVMinerva Neurosciences, Inc.

NERVMinerva Neurosciences, Inc.$5.10-0.97%

ENLVEnlivex Therapeutics Ltd.

ENLVEnlivex Therapeutics Ltd.$0.53-2.58%

XCURExicure, Inc.

XCURExicure, Inc.$1.91-3.54%

TAOXTAO Synergies Inc.

TAOXTAO Synergies Inc.$3.66+1.39%

CVKDCadrenal Therapeutics, Inc. Common Stock

CVKDCadrenal Therapeutics, Inc. Common Stock$3.60+13.56%

SONNSonnet BioTherapeutics Holdings, Inc.

SONNSonnet BioTherapeutics Holdings, Inc.$1.26-59.35%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$17.92-0.01%

TAT&T

TAT&T$20.58+0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.35-0.05%

CLROClearOne

CLROClearOne$6.48+1.01%

ONDSOndas

ONDSOndas$7.41-0.06%

NOKNokia

NOKNokia$12.07-0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.95+0.05%

Questions About NRSN

What is the current price of NeuroSense Therapeutics?

NeuroSense Therapeutics is trading at $0.71 per share.

What is the 52-week range for NeuroSense Therapeutics?

Over the past 52 weeks, NeuroSense Therapeutics has traded between $0.63 and $2.19.

How much debt does NeuroSense Therapeutics have?

As of the most recent reporting period, NeuroSense Therapeutics reported total debt of $73.00K.

How much cash does NeuroSense Therapeutics have on hand?

NeuroSense Therapeutics reported $3.41M in cash and cash equivalents in its most recent financial results.

What is NeuroSense Therapeutics’s dividend yield?

NeuroSense Therapeutics does not currently have a dividend yield.

NeuroSense Therapeutics

NeuroSense Therapeutics Financials at a Glance

NRSN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NeuroSense Therapeutics

NRSN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NeuroSense Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NRSN

What is the current price of NeuroSense Therapeutics?

What is the 52-week range for NeuroSense Therapeutics?

How much debt does NeuroSense Therapeutics have?

How much cash does NeuroSense Therapeutics have on hand?

What is NeuroSense Therapeutics’s dividend yield?

Premium Investing Services